BIOTEST AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 27.8 EUR | 0.00% |
|
-3.81% | -10.32% |
| May. 07 | Biotest Aktiengesellschaft Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Apr. 19 | Biotest Launches New Plasma Collection Center in Germany | MT |
Presenter SpeechMonika Buttkereit (Executives)Good morning, ladies and gentlemen. Welcome to t...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Biotest AG is a Germany-based provider of plasma proteins and biological drugs. The Company, with a chain that extends from pre-clinical and clinical development to worldwide marketing and distribution, mainly specializes in the areas of clinical immunology, hematology, and intensive care medicine. It develops, manufactures, and markets immunoglobulin, coagulation factors, and albumins based on human blood plasma. These are used for diseases of the immune and hematopoietic systems. In addition, the Company develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus, which are produced by recombinant technologies.
Sector
Pharmaceuticals
Calendar
2024-07-29
- Q2 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
27.8
EUR
Average target price
37
EUR
Spread / Average Target
+33.09%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -10.32% | 1.48B | |
| -3.35% | 88.91B | |
| +2.76% | 41.25B | |
| -14.17% | 31.99B | |
| +50.51% | 24.73B | |
| -15.09% | 15.54B | |
| -39.93% | 12.07B | |
| -9.08% | 12.05B | |
| -14.86% | 12.02B | |
| +6.22% | 8.84B |
- Stock Market
- Equities
- BIO3 Stock
- News Biotest AG
- Transcript : Biotest AG, Q3 2016 Earnings Call, Nov 10, 2016